Neoadjuvant chemotherapy for cervical cancer |
| |
Authors: | Moore David H |
| |
Institution: | Indiana University School of Medicine, 535 Barnhill Drive RT433, Indianapolis, IN 46202-5274, USA. dhmoore@iupui.edu |
| |
Abstract: | None of the current surgical or radiation treatment strategies for cervical cancer satisfactorily leads to a high disease-free survival and a low risk for treatment-related complications in patients with bulky or locally-advanced disease. Neoadjuvant chemotherapy (NACT) prior to surgery or radiation therapy has been studied as a means to reduce tumour bulk and thereby rendering subsequent therapy more effective. Impressive clinical response rates to cisplatin-based NACT have been achieved with acceptable toxicity and survival. Of the patients treated, approximately 20% will achieve a complete clinical response and many of these patients will prove to have a complete pathological response. Although there are too few randomised controlled studies to determine the effectiveness of NACT approaches, relative to standard treatments. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|